No spam - just the good stuff

Subscribe to our newsletter

News

Biotech

Merck bolsters neurodegeneration program with Caraway acquisition

Beyond Yamanaka: Mogrify demystifies cellular reprogramming

Loyal gets promising FDA feedback on lifespan extension drug for dogs

Company founder says FDA has formally accepted that a drug can be developed and approved to extend lifespan.

Quotient emerges with $50m to harness genetic variation at the cellular level

Vivodyne lands $38m to predict drug effects using lab-grown organs

Improving healthspan and longevity can be just like riding a bike

Over 30? Time to get proactive about health, longevity and disease prevention

GenSight to receive €4 million after completing second successful GMP batch of gene therapy

Will proteomics provide the answers to aging and longevity?

VectorY lands $138m to target neurodegeneration with vectorized antibodies

OrsoBio roars with $60m to treat metabolic disorders

Xenotransplantation comes of age

Forward Therapeutics lands $50m to target chronic inflammation

T3D’s Phase 2 Alzheimer’s trial yields promising results

Mogling Bio secures additional funding to advance rejuvenation tech

Can restoring elastin with existing drugs improve longevity?

BioAge announces Phase 2 trial of obesity drug

Will Turn Bio be the first longevity company to take cell rejuvenation to the clinic?

LyGenesis bags $19m to complete key clinical trial and advance cell therapy pipeline

Endogena gets FDA green light for AMD trial

ADDF backs Curasen with $5.8m to advance Alzheimer’s program

Amplifier doses first patients in trial and closes new financing

AbbVie targets Parkinson’s with $110m Mitokinin acquisition

AstronauTx blasts off with $61m for Alzheimer’s drug development

VitaDAO community launches its first biotech company

Beyond the secretome: targeting age-related immune decline

Gameto inks stem cell deal with Reprocell for female fertility program

‘We are so close to the future we want’

ExcepGen emerges from stealth, targets genetic medicine revolution

Rejuvenate Biomed announces positive results from sarcopenia clinical trial

Mogrify boosts Series A to $46m to advance cellular reprogramming therapies

Standing at the precipice of a biotech renaissance – the confluence of AI and SynBio

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.